Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Suven Life Sciences Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 9:23 pm

Market Cap 2,579 Cr.
Current Price 118
High / Low169/74.5
Stock P/E
Book Value 8.84
Dividend Yield0.00 %
ROCE36.4 %
ROE36.3 %
Face Value 1.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Suven Life Sciences Ltd

Competitors of Suven Life Sciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average15,004.70N/A43.76N/AN/A16.2516.45N/A

All Competitor Stocks of Suven Life Sciences Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales2144443343221
Expenses45293724252655343227493332
Operating Profit-43-28-32-20-21-22-52-32-28-24-46-30-31
OPM %-2,118%-2,340%-733%-467%-596%-494%-1,719%-1,208%-737%-768%-1,885%-1,267%-3,024%
Other Income50006026613644
Interest0000000000000
Depreciation1111222222221
Profit before tax-39-28-34-21-16-23-51-28-24-13-42-28-28
Tax %0%0%0%0%0%0%0%0%0%0%0%-4%0%
Net Profit-39-28-34-21-16-23-51-28-24-13-42-27-28
EPS in Rs-2.05-1.48-1.76-0.95-0.75-1.06-2.34-1.27-1.10-0.58-1.91-1.22-1.29

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales1121175214995436252861313121412
Expenses9610536139841442730012893134139140
Operating Profit1613159102129198-14-116-80-122-126-128
OPM %15%11%31%20%24%32%-5%-917%-593%-1,032%-929%-1,094%
Other Income1391921232714851429
Interest355665211100
Depreciation44121821211144476
Profit before tax116152981231960-106-77-122-118-106
Tax %-5%-32%28%26%29%37%15,038%-11%-7%0%0%-1%
Net Profit1181097287124-24-94-72-122-118-105
EPS in Rs0.650.485.703.764.576.48-1.25-4.94-3.78-5.59-5.42-4.82
Dividend Payout %26%35%7%35%15%15%-80%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2007-20082015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-27.27%-33.94%20.83%42.53%-119.35%-291.67%23.40%-69.44%3.28%11.02%
Change in YoY Net Profit Growth (%)0.00%-6.67%54.78%21.70%-161.88%-172.31%315.07%-92.85%72.72%7.74%

Suven Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2007-2008 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:-47%
3 Years:-5%
TTM:-32%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:-28%
TTM:-19%
Stock Price CAGR
10 Years:26%
5 Years:43%
3 Years:11%
1 Year:42%
Return on Equity
10 Years:%
5 Years:-57%
3 Years:-58%
Last Year:-36%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 7:33 pm

MonthMar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital6121313131313131315222222
Reserves96955475836547552261315882354248171
Borrowings41551098371343653210
Other Liabilities303810574781186233539121419
Total Liabilities173199773751816919303182128108389285212
Fixed Assets9611017230530630822252138372825
CWIP54107710250054000
Investments52003012792230045467674
Other Assets68834944391993085815710322305181113
Total Assets173199773751816919303182128108389285212

Reserves and Borrowings Chart

Cash Flow

MonthMar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +1641436810970-53-135-96-128-116-115
Cash from Investing Activity +-20-16-110-39-311-13014656-22-24894
Cash from Financing Activity +136179-68-30-525335146396-1
Net Cash Flow8-7212-39-23217-1814-5-432-22

Free Cash Flow

MonthMar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-25.00-42.0050.0019.0058.00164.00-17.00-122.00-85.00-125.00-128.00-129.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days531112839313636648402240
Inventory Days1972001651832223290
Days Payable73157897891134
Cash Conversion Cycle17715410514416223136648402240
Working Capital Days107139697363100237341,139285293123
ROCE %11%8%13%15%24%-4%-54%-68%-143%-53%-36%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters60.00%60.00%60.00%64.98%64.98%64.98%69.56%69.56%69.56%69.56%69.56%69.56%
FIIs0.41%0.44%0.52%0.45%0.45%0.48%0.46%0.51%0.48%0.50%0.54%0.46%
DIIs0.44%0.44%0.44%0.46%0.39%0.12%0.11%0.11%0.08%0.01%0.01%1.05%
Public39.15%39.12%39.04%34.11%34.18%34.41%29.85%29.80%29.88%29.92%29.88%28.91%
No. of Shareholders86,00881,47580,19581,03981,03880,11680,83878,63476,29180,95374,00368,959

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF6940.060.016942024-11-160%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)-4.82-6.63-9.57-5.67-7.40
Diluted EPS (Rs.)-4.82-6.63-9.57-5.67-7.40
Cash EPS (Rs.)-4.52-5.12-8.09-5.33-7.07
Book Value[Excl.RevalReserv]/Share (Rs.)12.3817.216.618.4911.26
Book Value[Incl.RevalReserv]/Share (Rs.)12.3817.216.618.4911.26
Revenue From Operations / Share (Rs.)0.530.620.811.061.13
PBDIT / Share (Rs.)-4.90-5.39-8.05-5.68-7.99
PBIT / Share (Rs.)-5.20-5.69-8.35-6.02-8.32
PBT / Share (Rs.)-4.86-5.42-8.39-6.09-8.36
Net Profit / Share (Rs.)-4.82-5.42-8.39-5.67-7.40
NP After MI And SOA / Share (Rs.)-4.82-5.42-8.39-5.67-7.40
PBDIT Margin (%)-914.01-867.37-988.42-536.50-705.39
PBIT Margin (%)-969.62-915.70-1025.51-568.75-734.31
PBT Margin (%)-907.20-873.52-1029.98-574.80-738.14
Net Profit Margin (%)-898.63-873.52-1029.98-535.31-653.62
NP After MI And SOA Margin (%)-898.63-873.52-1029.98-535.31-653.62
Return on Networth / Equity (%)-38.91-31.51-126.88-66.80-65.72
Return on Capital Employeed (%)-41.77-32.81-121.80-68.13-68.10
Return On Assets (%)-36.88-30.41-112.92-56.18-51.78
Long Term Debt / Equity (X)0.000.000.000.000.01
Total Debt / Equity (X)0.000.000.010.000.01
Asset Turnover Ratio (%)0.030.020.030.040.04
Current Ratio (X)18.9922.618.016.452.49
Quick Ratio (X)18.9422.618.016.452.49
Interest Coverage Ratio (X)-674.71-406.21-220.85-88.68-184.40
Interest Coverage Ratio (Post Tax) (X)-709.43-428.84-229.14-87.49-169.87
Enterprise Value (Cr.)2010.22872.721343.38849.81258.38
EV / Net Operating Revenue (X)171.9264.46113.4263.0517.92
EV / EBITDA (X)-18.81-7.43-11.47-11.75-2.54
MarketCap / Net Operating Revenue (X)185.9478.07113.8566.4818.90
Price / BV (X)8.052.8214.028.301.90
Price / Net Operating Revenue (X)185.9778.08113.8566.4818.90
EarningsYield-0.04-0.11-0.09-0.08-0.34

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Suven Life Sciences Ltd as of November 22, 2024 is: 49.10

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 22, 2024, Suven Life Sciences Ltd is Overvalued by 58.39% compared to the current share price 118.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Suven Life Sciences Ltd as of November 22, 2024 is: 50.23

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 22, 2024, Suven Life Sciences Ltd is Overvalued by 57.43% compared to the current share price 118.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: 2.29%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (307.69 cr) compared to borrowings (31.77 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (230.58 cr) and profit (4.75 cr) over the years.
  1. The stock has a low average ROCE of -23.92%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 167.50, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 99.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Suven Life Sciences Ltd:
    1. Net Profit Margin: -898.63%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -41.77% (Industry Average ROCE: 16.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -38.91% (Industry Average ROE: 16.45%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -709.43
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 18.94
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 43.76)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Suven Life Sciences Ltd. is a Public Limited Listed company incorporated on 09/03/1989 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1989PLC009713 and registration number is 009713. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11.84 Cr. and Equity Capital is Rs. 14.54 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Medical Research Services8-2-334, SDE Serene Chambers, 6th Floor, Avenue 7, Hyderabad Telangana 500034info@suven.com
http://www.suven.com
Management
NamePosition Held
Mr. Venkateswarlu JastiChairman & Managing Director
Mrs. Sudharani JastiWhole Time Director
Prof. Seyed E HasnainDirector
Mr. Santanu MukherjeeDirector
Mrs. J A S PadmajaDirector
Dr. Vajja Sambasiva RaoDirector

FAQ

What is the latest intrinsic value of Suven Life Sciences Ltd?

The latest intrinsic value of Suven Life Sciences Ltd as on 21 November 2024 is ₹49.10, which is 58.39% lower than the current market price of ₹118.00.

What is the Market Cap of Suven Life Sciences Ltd?

The Market Cap of Suven Life Sciences Ltd is 2,579 Cr..

What is the current Stock Price of Suven Life Sciences Ltd as on 21 November 2024?

The current stock price of Suven Life Sciences Ltd as on 21 November 2024 is ₹118.

What is the High / Low of Suven Life Sciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of Suven Life Sciences Ltd stocks is 169/74.5.

What is the Stock P/E of Suven Life Sciences Ltd?

The Stock P/E of Suven Life Sciences Ltd is .

What is the Book Value of Suven Life Sciences Ltd?

The Book Value of Suven Life Sciences Ltd is 8.84.

What is the Dividend Yield of Suven Life Sciences Ltd?

The Dividend Yield of Suven Life Sciences Ltd is 0.00 %.

What is the ROCE of Suven Life Sciences Ltd?

The ROCE of Suven Life Sciences Ltd is 36.4 %.

What is the ROE of Suven Life Sciences Ltd?

The ROE of Suven Life Sciences Ltd is 36.3 %.

What is the Face Value of Suven Life Sciences Ltd?

The Face Value of Suven Life Sciences Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Suven Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE